In silico prediction of ADME properties: Are we making progress?

Current Opinion in Drug Discovery and Development

Volumn 7, Issue 1, 2004, Pages 36-42

  Beresford, Alan P ^a   Segall, Matthew ^a   Tarbit, Michael H ^a  

^a Inpharmatica Ltd   (United Kingdom)

Author keywords

ADME; Computational models; Drug discovery; Drug metabolism; In silico

Indexed keywords

GLUCURONOSYLTRANSFERASE; POTASSIUM CHANNEL HERG; DRUG;

COMPUTER MODEL; DRUG ABSORPTION; DRUG DESIGN; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; DRUG RESEARCH; DRUG TRANSPORT; HIGH THROUGHPUT SCREENING; REVIEW; BIOLOGICAL MODEL; CHEMISTRY; COMPUTER SIMULATION; DRUG INDUSTRY; HUMAN; METABOLISM; PHARMACOKINETICS;

CHEMISTRY; COMPUTER SIMULATION; DRUG DESIGN; DRUG INDUSTRY; HUMANS; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS;

EID: 2942597675     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ: Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev (1997) 23(1-3):3-25. The original paper that introduced 'rule-based' thinking into chemistry selection before and after synthesis.
2. van de Waterbeemd H, Gifford E: ADMET in silico modelling: Towards prediction paradise? Nat Rev Drug Discov (2003) 2(3):192-204. A review of the current state of in silico ADME models by industrial practitioners.
3. Selick HE, Beresford AP, Tarbit MH: The emerging importance of predictive ADME simulation in drug discovery. Drug Disc Today (2002) 7(2):109-116. A speculation on the future role that predictive models will fulfil in drug design.
4. Boobis A, Gundert-Remy U, Kremers P, Macheras P, Pelkonen O: In silico prediction of ADME and pharmacokinetics. Report of an expert meeting organised by COST B15. Eur J Pharm Sci (2002) 17(4-5):183-193.
5. Ekins S, Kim RB, Leake BF, Dantzij AH, Schuetz EG, Lan LB, Yasuda K, Shepard RL, Winter MA, Schuetz JD, Wikel JH et al: Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein. Mol Pharmacol (2002) 61(5):964-973.
6. + channel blockers. J Med Chem (2002) 45(18):3844-3853.
7. Segall MD: Applications of Ab initio atomistic simulations to biology. J Phys: Cond Matt (2002) 14(11):2957-2973.
8. Jones JP, Mysinger M, Korzekwa KR: Computational models for cytochrome P450: A predictive electronic model for aromatic oxidation and hydrogen atom abstraction. Drug Metab Dispos (2002) 30(1):7-12. This paper describes the current leading approach to modeling compound liability to metabolism by CYP450s.
9. Park JY, Harris D: Construction and assessment of models of CYP2E1: Predictions of metabolism from docking, molecular dynamics, and density functional theoretical calculations. J Med Chem (2003) 46(9):1645-1660.
10. Williams PA, Cosme J, Sridhar V, Johnson EF, McRee DE: Microsomal cytochrome P450 2C5: Comparison to microbial P450s and unique features. J Inorg Biochem (2000) 81(3):183-190.
11. Williams PA, Cosme J, Ward A, Angove HC, Matak Vinkovic D, Jhoti H: Crystal structure of human cytochrome P450 2C9 with bound warfarin. Nature (2003) 424(6947):464-468. A paper which demonstrated that much of the preconceived thinking around pharmacophore models of cytochrome P450 will be challenged by knowledge of crystal structures.
12. Afzelius L, Zamora I, Ridderstrom M, Andersson TB, Karlen A, Masimirembwa CM: Competitive CYP2C9 inhibitors: Enzyme inhibition studies, protein homology modeling, and three-dimensional quantitative structure-activity relationship analysis. Mol Pharmacol (2001) 59(4):909-919.
13. Zamora I, Afzelius L, Cruciani G: Predicting drug metabolism: A site of metabolism prediction tool applied to the cytochrome P450 2C9. J Med Chem (2003) 46(12):2313-2324.
14. Engkvist O, Wrede P: High-throughput, in silico prediction of aqueous solubility based on one- and two-dimensional descriptors. J Chem Inf Comput Sci (2002) 42(5):1247-1249.
15. Liu R, So SS: Development of quantitative structure-property relationship models for early ADME evaluation in drug discovery. 1. Aqueous solubility. J Chem Inf Comput Sci (2001) 41(6):1633-1639.
16. Niwa T: Using general regression and probabilistic neural networks to predict human intestinal absorption with topological descriptors derived from two-dimensional chemical structures. J Chem Inf Comput Sci (2003) 43(1):113-119.
17. Liu R, Sun H, So SS: Development of quantitative structure-property relationship models for early ADME evaluation in drug discovery. 2. Blood-brain barrier penetration. J Chem Inf Comput Sci (2001) 41(6):1623-1632.
18. Bains W, Gilbert R, Sviridenko L, Gascon JM, Scoffin R, Birchall K, Harvey I, Caldwell J: Evolutionary computational methods to predict oral bioavailability QSPRs. Curr Opin Drug Discovery Dev (2002) 5(1):44-51.
19. Nicolotti O, Gillet VJ, Fleming PJ, Green OV: Multiobjective optimization in quantitative structure-activity relationships: Deriving accurate and interpretable QSARs. J Med Chem (2002) 45(23):5069-5080.
20. Wessel MD, Jurs PC, Tolan JW, Muskal SM: Prediction of human intestinal absorption of drug compounds from molecular structure. J Chem Inf Comput Sci (1998) 38(4):726-735.
21. Stenberg P, Norinder U, Luthman K, Artursson P: Experimental and computational screening models for the prediction of intestinal drug absorption. J Med Chem (2001) 44(12):1927-1937.
22. Platts JA, Abraham MH, Butina D, Hersey A: Estimation of molecular linear free energy relationship descriptors by a group contribution approach. 2. Prediction of partition coefficients. J Chem Inf Comput Sci (2000) 40(1):71-80.
23. Zhao YH, Le J, Abraham MH, Hersey A, Eddershaw PJ, Luscombe CN, Butina D, Beck G, Sherbome B, Cooper I, Platts JA: Evaluation of human intestinal absorption data and subsequent derivation of a quantitative structure-activity relationship (QSAR) with the Abraham descriptors. J Pharm Sci (2001) 90(6):749-784.
24. Crivori P, Cruciani G, Carrupt PA, Testa B: Predicting blood-brain barrier permeation from three-dimensional molecular structure. J Med Chem (2000) 43(11):2204-2216.
25. DeWitte RS: On experimental design in drug discovery. Curr Drug Disc (2002) February:19-22. An entertaining and readable account of the hidden dangers in the practice of filtering drugs using screens and models.
26. Ekins S, Boulanger B, Swaan PW, Hupcey MA: Towards a new age of virtual ADME/Tox and multidimensional drug discovery. J Comput Aided Mol Des (2002) 16(5-6):381-401. A good perspective on the need for integrating data and predictions from ADME models.
27. Martin EJ, Critchlow RE: Beyond mere diversity: Tailoring combinatorial libraries for drug discovery. J Comb Chem (1999) 1(1):32-45.
28. Zheng W, Hung ST, Saunders JT, Seibel GL: PICCOLO: A tool for combinatorial library design via multicriterion optimization. Pac Symp Biocomput (2000):588-599.
29. Matter H, Baringhaus KH, Naumann T, Klabunde T, Pirard B: Computational approaches towards the rational design of drug-like compound libraries. Comb Chem High Throughput Screen (2001) 4(6):453-475.
30. Agrafiotis DK: Multiobjective optimization of combinatorial libraries. IBM J Res Dev(2001) 45(3/4):545-566.
31. Gillet VJ, Khatib W, Willett P, Fleming PJ, Green DV: Combinatorial library design using a multiobjective genetic algorithm. J Chem Inf Comput Sci (2002) 42(2):375-385.
32. Beresford AP, McGibney D, Humphrey MJ, Macrae PV, Stopher DA: Metabolism and kinetics of amiodipine in man. Xenobiotica (1988) 18(2):245-254.
33. Yoshida F, Topliss JG: QSAR model for drug human oral bioavailability. J Med Chem (2000) 43(13):2575-2585.
34. Yu H, Adedoyin A: ADME-Tox in drug discovery: Integration of experimental and computational technologies. Drug Disc Today (2003) 8(18):852-861.
35. Arlington S, Hughes S, Barnett S, Palo J: Pharma 2010: The Threshold of Innovation. (2002) IBM Business Consulting Services, Reference type: Report.
36. Rose S: Statistical design and application to combinatorial chemistry. Drug Dis Today (2002) 7(2):133-138.